Emcure Receives 7 US FDA Observations at Sanand Facility

Emcure Pharmaceuticals discloses US FDA inspection results at its Sanand formulations facility from May 6-15, 2026.
The inspection concluded with a Form 483 containing 7 observations, described as procedural in nature by the company.
The company states it is comprehensively addressing the observations and will respond to US FDA within stipulated timeframe.